Catégorie : Biotech

BLENDS

by jbertholdin Biotech, Institutions, Service Providers & others, Medtech, Pharma

BLENDS

About the company

Founded in 2023, Blends provides research intelligence for biotech companies and labs.

They deliver state-of-the-art systematic reviews within 24 hours using advanced methodologies, ensuring comprehensive and timely analysis that supports faster and more informed decision-making in research and development projects.

Their cutting-edge monitoring tools enhance productivity and effectiveness by offering real-time updates, enriched data, and unique insights into scientific developments. This includes features like Live, Reports, Trends, and Context, which transform how biotech information is accessed, analyzed, and applied, driving innovation and efficiency in the industry.

About the solution


Their cutting-edge monitoring tool is designed to keep researchers and labs fully informed about relevant scientific developments. It stands out with four main features: Live, Reports, Trends, and Context, each offering unique insights. Their platform enriches public data, providing summaries, key conclusions, importance indicators, and more, making research more exploitable than ever. Unlike competitors, their Context feature uniquely identifies analogies in unrelated research, fostering interdisciplinary breakthroughs.

Website
Key information

– Therapeutic areas: All therapeutic areas

– Based in: Versailles (FRANCE)

– Employees: 11 – 50

– Created in: 2023

OKOMERA

by jbertholdin Biotech

OKOMERA

About the company

Okomera specializes in automated 3D organoid screening technology that accelerates access to improved, precision-based cancer therapies. Their goal is to advance personalized medicine by providing healthcare actors with powerful tools to analyze how tumors respond to various therapies. 

Okomera integrates standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.

About the solution

They have developed a miniaturized 3D assay to help clinical decision. Using a biopsy of the tumor, Okomera’s cell culture technology includes: a fluidic machine, reagents, and a software analysis designed to estimate and identify the best drug treatment for each cancer patient.

Website
Key information

– Therapeutic areas: Oncology, Assays on chip, Drug discovery

– Based in: Paris (FRANCE)
Berkeley (US)

– Employees: 11 – 50

– Created in: 2020

SURGIMAB

by jbertholdin Biotech, Pharma

SURGIMAB

About the company

SurgiMab’s tumor-targeting fluorescent molecules enable real time visualization of tumor margins and micro-tumors which are invisible to the naked eye.

After injection to the patient, SurgiMab’s lead molecule SGM-101 specifically targets various lesions such as colorectal, pancreas or lung tumors. Surgical navigation then allows tumors to be displayed intra-operatively, allowing complete resection. In case of recurrent cancer, when fibrotic tissue sometimes impairs the surgeon’s vision, it can also help the surgeon preserve important structures.
Intraoperative tumor imaging with SurgiMab’s targeted molecules represents a real-time improvement in the intraoperative differentiation between normal and cancer tissue. It will participate in the new paradigm-shift in cancer surgery: surgeons will improve patient outcome while lowering health-care costs.

SurgiMAb was created in 2011. SGM-101 is currently tested in the clinic in the USA and Europe, including two Phase 3 studies.
SurgiMab is seeking additional financing and/or parners to get to the market.

About the solution

As opposed to an indiscriminate contrast agent, this ability to specifically highlight malignant tissue during a procedure opens up a broad market in both Fluorescence Guided Surgery and potentially also in cancer screening.

SurgiMab’s technique of intraoperative detection of tumors combines the specificity of monoclonal antibodies and the sensitivity of fluorescent detection. To date SGM-101 is the only cancer-targeting fluorescent molecule with efficacy demonstrated in the clinic for several digestive tumors. Surgeons can rely on fluorescence imaging to assess surgical margins, accurately stage cancer and detect small invisible metastases or to spare normal tissue.

Website
Key information

– Therapeutic areas: Oncology, Surgery, Molecular Imaging

– Based in: Montpellier (FRANCE)

– Employees: 1-10

– Created in: 2011

ROOWIN SA

by jbertholdin Biotech, Institutions, Service Providers & others, Pharma

ROOWIN SA

About the company

Roowin is a privately owned Contract Research Organisation (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value added fine chemistry, Roowin offers a large range of chemical services.

They support their customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).

About the solution

They are a french company specializing in high-value fine chemistry, is well-equipped to support biotech companies in need of GLP and GMP lots for toxicology studies and IND applications. With expertise in GMP synthesis and a focus on assisting customers from early research to later stages, Roowin is a potential partner for biotechs developing new clinical candidates.

Website
Key information

– Therapeutic areas: All therapeutic area

– Based in: La Varenne (FRANCE), Offices in San Diego (US)

– Employees: 11-50

– Created in: 1998

BIOASTER

by jbertholdin Biotech, Pharma

BIOASTER

About the company

BIOASTER is the first Institute for Technological Innovation in Microbiology in France (Lyon and Paris, Pasteur Institute). They are Non-for-profit Technology Research Institute, active in the field of vaccine, immunomodulation, microbiota, anti-infectives, and IVD.
With BIOASTER, each project benefits from the right scientific and technology mix to address specific issues, quality in execution to meet high-standard requirements and case-by-case financial risk-sharing partnerships.
Their industrial partners come from a wide range of industries, including pharma, biotech, animal health, nutrition and diagnostics.

About the solution

Examples of partnership themes include for vaccine : Memory response /Longitudinal study, Efficacy, Memory response /Longitudinal study,correlate of protection, Breadth of protection, benchmarking with competitives vaccines, vaccine & adjuvant MOA, Exploratory research, preclinical & clinical biomarkers identification, system serology, immunometabolism (immunophenotyping at single cell), microbiota & immunity, host pathogen interaction.

Examples of partnership themes include for bioprocess- bioproduction & CMC: biomarkers identification for batch success/batch failure, digital tween & machine learning/deep Learning, method development & benchmarking, antigen characterization, potency assays development, Host Cell Proteins identification, CMC methods for in vitro mRNA production, mRNA formulation.

Website
Key information

– Therapeutic areas: Infectious & therapeutic vaccines, Immunology, Auto-immune diseases, Inflammatory diseases, Immuno-modulation, Microbiota, Antimicrobial, Antiviral, Ivd, Support to bioprocess optimization & bioproduction, Support to cmc

– Based in: Paris & Lyon (FRANCE)

– Employees: 51 – 200

– Created in: 2012

RONDOL INDUSTRIE

by jbertholdin Biotech, Medtech, Pharma

RONDOL INDUSTRIE

About the company

Rondol Industrie have been created in 2012 with the goal of adapting hot melt extrusion technology to the micro scale and to Pharma standards, thereby contributing to better and cheaper healthcare.

Their team aims to leverage their combined 60 years of experience in extrusion technologies to offer a range of energy-efficient machines that would enable pharmaceutical companies to conduct trials and manufacture in better and cheaper formulations.

Along the way, they realized that their extrusion machines were capable of much more than initially expected. They can now produce a diverse range of extruded products via custom dies.

About the solution


Best of all, their vertical extruders are much smaller than traditional machines, saving on expensive footprint and material costs. Ease of cleaning also enables a quick turnaround between production lots or trials.

They are proud of what they have achieved so far – ground-breaking improvements in the bioavailability of aspirin for cancer treatment and reformulation of anti-malarial drugs to be suitable for children, among numerous other drug and medical implant trials. They are growing partnerships with industry and academia in Canada, England, France, Germany, Northern Ireland, and the USA. They have twice been nominated for a Galien Award in 2020 and 2023.

Website
Key information

–  Therapeutic areas: Hot Melt Extruders for Drug Formulation and Medical Device

–  Based in: Nancy (FRANCE)

–  Employees: 1-10

–  Created in: 2012

SEQENS

by jbertholdin Biotech, Pharma

SEQENS

About the company

SEQENS is a global partner in health, personal care and specialty ingredients. They empower innovation to bring the best solutions to our customers, with a constant concern for sustainability. Relying on the skills of 3300 employees, they leverage a worldwide manufacturing network, and state-of-the-art R&D centers.
As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. They innovate, develop and industrialize the most demanding molecules, and implement the best available technologies.

As a leading player of the health industry, SEQENS is committed to the therapies of the future and personalized medicine.

Driven by a culture of excellence and a strong entrepreneurial spirit, they share values such as unity, agility, and reactivity. They provide the highest level of service and quality to more than 1500 customers around the world while acting ethically in accordance to our strong CSR program.

About the solution

Streamline your development process with Seqens’ one-stop-shop CDMO services. They offer integrated support for all stages of your program, from discovery and preclinical studies to clinical development, market authorization, and even ongoing commercial manufacturing. This ensures seamless handoffs and reduces overall development timelines.

Website
Key information

– Therapeutic areas: Oncology

– Based in: Ecully (FRANCE) & Devens (Boston, US)

– Employees: 500+

– Created in: 2003

MAAT PHARMA

by jbertholdin Biotech, Pharma

MAAT PHARMA

About the company

MaaT Pharma is the leading microbiome company in oncology.
The Company owns in-house cGMP manufacturing capacities and specializes in developing Microbiome Ecosystem Therapies dedicated to enhancing the survival of cancer patients, with a focus on treating and preventing complications in blood cancers and improving treatments in immuno-oncology.

About the solution

MaaT013, a pooled-donor microbiome ecosystem therapy, is a non-immunosuppressive treatment dedicated to treat acute GvHD.
As of today, MaaT013 has been administered to more than 200 patients.
A Phase 3 trial is currently ongoing with ORR results expected in mid-2024.
The Company has an open-IND granted by the U.S. FDA and has engaged active discussions with prominent US clinicians in the field of stem cell transplantation to explore the most efficient path forward to introduce MaaT013 to patients in the United States.
MaaT013 has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

MaaT033, a donor-derived, high-richness, high-diversity oral Microbiome Ecosystem TherapyTM containing is currently ongoing Phase 2 as an adjunctive therapy to improve overall survival in patients receiving HSCT and other cellular therapies.
MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA) in August 2023.

Website
Key information

– Therapeutic areas: Oncology, Hemato-Oncology: acute Graft-versus-Host Disease (aGvHD), allogenic hematopoietic stem cell transplantation; Immuno-oncology: metastatic melanoma; Neurodegenerative diseases : Amyotrophic lateral sclerosis (ALS).

– Based in: Lyon (FRANCE)

– Employees: 51-200

– Created in: 2014

AMKBIOTECH

by jbertholdin Biotech, Digital Health, Pharma

AMKBIOTECH

About the company

AMKbiotech is an innovative service laboratory proving highplex tissue imaging solutions for biomarker identification and target efficacy validation.

About the solution

AMKbiotech combines the development of a novel tissue processing and imaging approach with AI-based analytical tools to generate 200 times more data from a single tissue section, while saving 80% of the resources needed for such analysis with classical histology approaches, in a 2 times faster execution period.

Website
Key information

–  Therapeutic areas: Histopathology, Oncology, Dermatology, Inflammatory disease

–  Based in: Sophia-Antipolis (FRANCE)

–  Employees: 1-10

–  Created in: 2021

CILCARE

by jbertholdin Biotech, Pharma

CILCARE

About the company

Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. They believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.


Founded in 2014 by three women with extensive backgrounds in the pharmaceutical industry, Cilcare initially aimed to address the significant unmet medical needs in ear diseases. Its approach focuses on translational research, supported by a cutting-edge R&D platform with robust pharmacological models. Partnering with CBSET, a translational institute linked to the MIT in 2017, Cilcare accelerated its mission, to drive transformative breakthroughs. Developing its own assets coupled with a unique AI-driven approach, Cilcare focuses on cochlear synaptopathy treatment and associated neuro-inflammatory disorders.

About the solution

Cilcare stands out with a revolutionary strategy that merges drug development with state-of-the-art AI-driven approach, specifically tailored for auditory data analysis. Cilcare’s lead compound, CIL001, is ready to enter phase IIA in the treatment of cochlear synaptopathy, a hot topic in the scientific community, and affecting 15% of the population. Addressing an underexplored therapeutic domain, with a unique pharmacological pathway, position Cilcare and its lead compound at the forefront of innovation in the field of auditory sciences.

Website
Key information

–  Therapeutic areas: Hearing disorders, Deafness, Tinnitus, Cochlear Synaptopathy, Otology, Auditory health and associated neuro-inflammatory diseases

–  Based in: Headquarter and Labs : Montpellier (FRANCE) Office : Paris (FRANCE) Office and Labs : Boston (US)

–  Employees: 11 – 50

–  Created in: 2014